T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.

Abstract : We report herein the results we obtained and the limitations we experienced during the production and use of a bank of Epstein-Barr virus (EBV)-transformed human cytotoxic T lymphocytes (EBV-CTLs). To assess the feasibility and toxicity of this strategy, we selected and stored, in liquid nitrogen, 4 billion EBV-CTLs from each of the 13 selected donors. Subsequently, in a multicenter phase I/II study, 11 patients with EBV-associated lymphoma resistant to conventional treatments received 1-3 doses of 5 million EBV-CTLs/kg with 1-3 and 0-4 compatibilities for human leukocyte antigen (HLA)-I and HLA-II, respectively. Except for one event of fever after injection, no immediate or delayed toxicity, no graft versus host disease, and no graft rejection attributable to CTL infusion were observed. Three patients presented complete remission and 1 partial remission after treatment. Considering the clinical options currently available, and the constrains associated with CTL preparation and implementation, we conclude that CTL banks should consist of a reasonably small number of cell lines with documented specificities. This objective could be more easily achieved if the few homozygous donors for the most frequent HLA alleles of the targeted population could be made available for such a project.
Type de document :
Article dans une revue
Journal of Immunotherapy, Lippincott, Williams & Wilkins, 2014, 37 (3), pp.170-9. 〈10.1097/CJI.0000000000000031〉
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-01256575
Contributeur : Ghislaine Calvez <>
Soumis le : vendredi 15 janvier 2016 - 09:12:29
Dernière modification le : lundi 16 octobre 2017 - 01:17:34

Identifiants

Citation

Géraldine Gallot, Solène Vollant, Soraya Saïagh, Béatrice Clémenceau, Régine Vivien, et al.. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.. Journal of Immunotherapy, Lippincott, Williams & Wilkins, 2014, 37 (3), pp.170-9. 〈10.1097/CJI.0000000000000031〉. 〈hal-01256575〉

Partager

Métriques

Consultations de la notice

176